Classic view of this page
Quantitative PML-RARA Transcipt Detection for Acute Promyelocytic Leukemia
Clinical Genetic Test
Help
offered by
Molecular Oncology Laboratory, LabCorp
View lab's test page
LinkOut
GTR Test Accession: Help GTR000613125.1
CAP
IMMUNOLOGYINHERITED DISEASECANCER ... View more
Last updated in GTR: 2023-12-08
View version history
Last annual review date for the lab: 2023-12-08 LinkOut
At a Glance
Test purpose: Help
Prognostic
Conditions (1): Help
Acute promyelocytic leukemia
Genes (1): Help
RARA (17q21.2)
Methods (1): Help
Molecular Genetics - Targeted variant analysis: Quantitative PCR (qPCR)
Target population: Help
Not provided
Clinical validity: Help
Not provided
Clinical utility: Help
Not provided
Ordering Information
Offered by: Help
Molecular Oncology Laboratory, LabCorp
View lab's test page
Test short name: Help
APL
Specimen Source: Help
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
Informed consent required: Help
Decline to answer
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
Test Order Code, How to Order, Lab contact for this test, Test strategy, Test development
Conditions Help
Total conditions: 1
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 1
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 1
Method Category Help
Test method Help
Instrument *
Targeted variant analysis
Quantitative PCR (qPCR)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Prognostic
Recommended fields not provided:
Clinical validity, Clinical utility, Target population, What is the protocol for interpreting a variation as a VUS?, Are family members with defined clinical status recruited to assess significance of VUS without charge?, Will the lab re-contact the ordering physician if variant interpretation changes?, Is research allowed on the sample after clinical testing is complete?, Sample negative report, Sample positive report
Technical Information
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
In vitro studies have indicated that this assay has an analytical sensitivity that allows for the detection of 0.001% PML-RARA/ABL1.
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
Yes

Method used for proficiency testing: Help
Formal PT program

PT Provider: Help
College of American Pathologists, CAP

CAP Testing Information Help
Minimal Residual Disease, PML/RARA; PML/RARA; MRD2
Recommended fields not provided:
Test Confirmation, Assay limitations, Description of internal test validation method, Citations for Analytical validity, Description of PT method
Regulatory Approval
FDA Review: Help
Not provided
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.